Scrip
Dendreon's Provenge prolongs prostate cancer survival in Phase III
15 April 2009
Katie McQue
Dendreon's novel cancer immunotherapy Provenge (sipuleucel-T) has met the primary endpoint of its Phase III IMPACT trial of improving overall survival in men with advanced prostate cancer.
The company says that this data will be filed as an amendment to its existing BLA in the fourth quarter...
Please Login to read the full article.
15 April 2009
Katie McQue
The company says that this data will be filed as an amendment to its existing BLA in the fourth quarter...
Please Login to read the full article.
RELATED CONTENT
NEWS
- EU's CHMP negative on Antigenics' therapeutic cancer vaccine Oncophage
- Dendreon's Provenge becomes first therapeutic cancer vaccine to be approved in US
- BMS's immunotherapy ipilimumab shows survival benefit in Phase III advanced melanoma trial
- GTx slapped with "surprise" complete response letter for toremifene
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
